EP3452033A4 - Pharmaceutical ophthalmic compositions and methods for fabricating thereof - Google Patents

Pharmaceutical ophthalmic compositions and methods for fabricating thereof Download PDF

Info

Publication number
EP3452033A4
EP3452033A4 EP17793224.1A EP17793224A EP3452033A4 EP 3452033 A4 EP3452033 A4 EP 3452033A4 EP 17793224 A EP17793224 A EP 17793224A EP 3452033 A4 EP3452033 A4 EP 3452033A4
Authority
EP
European Patent Office
Prior art keywords
fabricating
methods
ophthalmic compositions
pharmaceutical ophthalmic
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17793224.1A
Other languages
German (de)
French (fr)
Other versions
EP3452033A1 (en
Inventor
William Wiley
Richard Dilzer
Dennis Elias Saadeh
Jeffrey T. Liegner
John Scott Karolchyk
Bernard Covalesky
Kallan Peters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harrow IP LLC
Original Assignee
Harrow IP LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/148,574 external-priority patent/US20160243031A1/en
Priority claimed from US15/178,812 external-priority patent/US20160279055A1/en
Application filed by Harrow IP LLC filed Critical Harrow IP LLC
Publication of EP3452033A1 publication Critical patent/EP3452033A1/en
Publication of EP3452033A4 publication Critical patent/EP3452033A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
EP17793224.1A 2016-05-06 2017-05-03 Pharmaceutical ophthalmic compositions and methods for fabricating thereof Withdrawn EP3452033A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/148,574 US20160243031A1 (en) 2013-07-22 2016-05-06 Pharmaceutical ophthalmic compositions and methods for fabricating thereof
US15/178,812 US20160279055A1 (en) 2013-07-22 2016-06-10 Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
PCT/US2017/030772 WO2017192675A1 (en) 2016-05-06 2017-05-03 Pharmaceutical ophthalmic compositions and methods for fabricating thereof

Publications (2)

Publication Number Publication Date
EP3452033A1 EP3452033A1 (en) 2019-03-13
EP3452033A4 true EP3452033A4 (en) 2020-02-12

Family

ID=60203416

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17793224.1A Withdrawn EP3452033A4 (en) 2016-05-06 2017-05-03 Pharmaceutical ophthalmic compositions and methods for fabricating thereof

Country Status (6)

Country Link
EP (1) EP3452033A4 (en)
JP (1) JP6694525B2 (en)
KR (2) KR20190109604A (en)
AU (1) AU2017260327B2 (en)
CA (1) CA3023243C (en)
WO (1) WO2017192675A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019043169A1 (en) * 2017-09-01 2019-03-07 Murray & Poole Enterprises, Ltd Methods and compositions for the treatment of ophthalmic conditions
US11071724B2 (en) 2019-05-17 2021-07-27 Ocular Science, Inc. Compositions and methods for treating presbyopia
MX2022015836A (en) * 2020-06-10 2023-03-28 Ocular Science Inc Compositions and uses in method for post-operative ocular care.
WO2022092868A1 (en) * 2020-10-29 2022-05-05 주식회사태준제약 Ophthalmic composition

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150025511A1 (en) * 2013-07-22 2015-01-22 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20150164882A1 (en) * 2013-07-22 2015-06-18 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20160101118A1 (en) * 2014-08-15 2016-04-14 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716830B2 (en) * 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
KR100722502B1 (en) * 1999-09-24 2007-05-28 알콘, 인코퍼레이티드 Topical suspension formulations containing ciprofloxacin and dexamethasone
US20070148192A1 (en) * 2003-02-21 2007-06-28 Laddha Ritu N Stable ophthalmic composition
US20050085446A1 (en) * 2003-04-14 2005-04-21 Babu M.K. M. Fluoroquinolone formulations and methods of making and using the same
US7109247B2 (en) * 2003-05-30 2006-09-19 3M Innovative Properties Company Stabilized particle dispersions containing nanoparticles
US7799331B2 (en) * 2005-08-04 2010-09-21 Taro Pharmaceutical North America, Inc. Oral suspension of prednisolone acetate
RU2010126096A (en) * 2007-11-27 2012-01-10 Алькон Рисерч, Лтд. (Us) OPHTHALMIC OR EAR PREPARATIVE FORMS IN THE FORM OF EXTERNAL USE SOLUTION CONTAINING MOXIFLOCCINE HYDROCHLORIDE AND DEXAMETASONE PHOSPHATE
UA119324C2 (en) * 2013-04-02 2019-06-10 Теміс Медікер Лімітед Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives
WO2015012899A1 (en) * 2013-07-22 2015-01-29 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration comprising an antibacterial agent and an antiinflammatory agent

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150025511A1 (en) * 2013-07-22 2015-01-22 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20150164882A1 (en) * 2013-07-22 2015-06-18 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20160101118A1 (en) * 2014-08-15 2016-04-14 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2017192675A1 *

Also Published As

Publication number Publication date
EP3452033A1 (en) 2019-03-13
CA3023243A1 (en) 2017-11-09
KR20180126087A (en) 2018-11-26
AU2017260327B2 (en) 2018-12-20
JP6694525B2 (en) 2020-05-13
AU2017260327A1 (en) 2018-11-29
JP2019514975A (en) 2019-06-06
WO2017192675A1 (en) 2017-11-09
KR20190109604A (en) 2019-09-25
CA3023243C (en) 2020-01-21

Similar Documents

Publication Publication Date Title
EP3436482A4 (en) Antibodies, pharmaceutical compositions and methods
EP3500255A4 (en) Ophthalmic pharmaceutical compositions and uses relating thereto
EP3426348A4 (en) 3-desoxy derivative and pharmaceutical compositions thereof
GB201913962D0 (en) Ophthalmic drug compositions
EP3491026A4 (en) Human antibodies, pharmaceutical compositions and methods
EP3472317A4 (en) Compositions and methods for reducing ocular neovascularization
EP3513809A4 (en) Medicinal composition
EP3452075A4 (en) Ophthalmic pharmaceutical composition
EP3412660A4 (en) Sulfonamide derivative and pharmaceutical composition containing same
EP3434285A4 (en) Pharmaceutical composition and use thereof
EP3541385A4 (en) Pharmaceutical formulations
EP3442543A4 (en) Compositions and methods for neuralgenesis
EP3412665A4 (en) Suvorexant intermediate and preparation method thereof
EP3052095A4 (en) Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof
EP3438105A4 (en) Diaryl- -lactam compound and preparation method and pharmaceutical use thereof
EP3348260A4 (en) Pharmaceutical tramadol composition for ophthalmic use
EP3398598A4 (en) Sulfonamide derivative and preparation method and use thereof
EP3436467A4 (en) Novel compositions and therapeutic methods
EP3503873A4 (en) Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof
EP3554486A4 (en) Pharmaceutical formulations for treating glaucoma and methods for fabricating and using thereof
EP3424899A4 (en) Sacubitril intermediate and preparation method thereof
EP3721890A4 (en) Ophthalmic drug preparation and uses thereof
EP3491458A4 (en) Ophthalmic devices and related methods
EP3528787A4 (en) Pharmaceutical formulations and methods of making the same
EP3185873A4 (en) Pharmaceutical composition and methods

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20181120

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: HARROW HEALTH, INC.

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: HARROW IP, LLC

A4 Supplementary search report drawn up and despatched

Effective date: 20200115

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/14 20060101ALI20200109BHEP

Ipc: A61K 47/10 20170101ALI20200109BHEP

Ipc: A61K 31/47 20060101ALI20200109BHEP

Ipc: A61K 31/4709 20060101ALI20200109BHEP

Ipc: A61K 47/26 20060101ALI20200109BHEP

Ipc: A61P 27/02 20060101ALI20200109BHEP

Ipc: A61K 45/06 20060101ALI20200109BHEP

Ipc: A61K 31/573 20060101ALI20200109BHEP

Ipc: A61K 47/38 20060101ALI20200109BHEP

Ipc: A61K 31/196 20060101AFI20200109BHEP

Ipc: A61K 31/496 20060101ALI20200109BHEP

Ipc: A61K 9/10 20060101ALI20200109BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40012052

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20201105

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20210316